# Article information:

Therapeutic pipeline in nonalcoholic steatohepatitis | Nature Reviews Gastroenterology & Hepatology  
<https://www.nature.com/articles/s41575-020-00408-y>

# Article summary:

1. There is a robust therapeutic pipeline for nonalcoholic steatohepatitis (NASH) with potential benefits that extend beyond the liver.

2. NASH pathophysiology is complex and involves genetic determinants, comorbidities, environmental factors, and behavioural factors.

3. Clinical trials have shown that NASH can progress to cirrhosis in up to 20% of patients, and that fibrosis stage is the single most important predictor of liver-related mortality.

# Article rating:

Appears moderately imbalanced: The article provides some useful information, but is missing several important points or pieces of evidence that would be required to present the discussed topics in a balanced and reliable way. You are encouraged to seek a more balanced perspective on the presented issues by exploring the provided research topics and looking at different information sources.

# Article analysis:

The article provides an overview of the current therapeutic pipeline for nonalcoholic steatohepatitis (NASH). The article is well-written and provides a comprehensive review of the available treatments and their efficacy in clinical trials. The authors provide a detailed description of the pathophysiology of NASH, including genetic determinants, associated comorbidities, environmental factors, and behavioural factors.

The article does not discuss any potential biases or sources of bias in the clinical trials discussed. It also does not explore any counterarguments or present both sides equally when discussing potential treatments for NASH. Additionally, there is no discussion of possible risks associated with these treatments or how they may affect patient outcomes.

In conclusion, this article provides a comprehensive overview of the current therapeutic pipeline for nonalcoholic steatohepatitis (NASH). However, it does not discuss any potential biases or sources of bias in the clinical trials discussed nor does it explore any counterarguments or present both sides equally when discussing potential treatments for NASH. Additionally, there is no discussion of possible risks associated with these treatments or how they may affect patient outcomes.

# Topics for further research:

* Nonalcoholic steatohepatitis treatment risks
* Clinical trial bias in NASH
* Counterarguments to NASH treatments
* Environmental factors in NASH
* Genetic determinants of NASH
* Behavioural factors in NASH

# Report location:

<https://www.fullpicture.app/item/76e88af59ad038c87b42c7bc25244909>